Pronethalol

Pronethalol (also known as nethalide or compound 38,174; trade name Alderlin) was an early non-selective beta blocker clinical candidate. It was the first beta blocker to be developed by James Black and associates at Imperial Chemical Industries, and the first to enter clinical use, in November 1963.^[1]

Pronethalol

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Withdrawn
Identifiers
IUPAC name 1-(naphthalen-2-yl)-2-(propan-2-ylamino)ethanol
CAS Number	54-80-8 Y
PubChem CID	4930
ChemSpider	4761
UNII	XBP4RT1IMQ
ChEMBL	ChEMBL16476
CompTox Dashboard (EPA)	DTXSID8021193
Chemical and physical data
Formula	C15H19NO
Molar mass	229.323 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O

However, it was never used widely due to carcinogenicity in mice, which was thought to result from formation of a carcinogenic naphthalene epoxide metabolite,^[2] and was superseded by propranolol from 1965 onward.^[1]

See also

• Beta blocker
• Discovery and development of beta-blockers
• Naphthylaminopropane